The candidate agents extend current antibiotics classes with, for example, second-generation polymyxins (MRX-8 and upleganan, both in Phase I), an aminoglycoside (apramycin, Phase I), a tetracycline (zifanocycline, Phase I) and a macrolide (nafithromycin, Phase II) as well as new beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations (ceftibuten/ledaborbactam, Phase I
We did not receive any public comments on our proposed labor-related share, and we are finalizing our proposal without modification
Do not guess
The 15-residue synthetic fragment was numbered 157 within the original research nomenclature used by the discovering group, producing the BPC-157 designation that subsequently became the standard name in published literature
Accessed 24 June 2024
Rottenberg, H., & Hoek, J